Research Analysts Offer Predictions for HRMY FY2025 Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Harmony Biosciences in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan anticipates that the company will post earnings per share of $3.71 for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $58.00 price target on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share.

Other research analysts also recently issued research reports about the stock. Oppenheimer restated an “outperform” rating and set a $59.00 price objective (up previously from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Raymond James reissued an “outperform” rating and set a $40.00 price target on shares of Harmony Biosciences in a report on Thursday, October 10th. HC Wainwright reiterated a “buy” rating and set a $75.00 price objective on shares of Harmony Biosciences in a research report on Thursday, January 16th. Needham & Company LLC reissued a “buy” rating and issued a $52.00 target price on shares of Harmony Biosciences in a research report on Monday, January 13th. Finally, Mizuho upped their price target on shares of Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a research report on Thursday, October 10th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $55.00.

Harmony Biosciences Price Performance

HRMY opened at $40.46 on Wednesday. The company’s 50-day simple moving average is $34.46 and its two-hundred day simple moving average is $34.96. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. The stock has a market capitalization of $2.31 billion, a P/E ratio of 19.18, a P/E/G ratio of 0.54 and a beta of 0.78. Harmony Biosciences has a 52-week low of $28.14 and a 52-week high of $41.61.

Harmony Biosciences (NASDAQ:HRMY) last posted its earnings results on Tuesday, October 29th. The company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The business had revenue of $186.00 million during the quarter, compared to analyst estimates of $184.07 million. During the same quarter last year, the company earned $0.63 EPS. The company’s quarterly revenue was up 16.0% compared to the same quarter last year.

Hedge Funds Weigh In On Harmony Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HRMY. Envestnet Asset Management Inc. increased its holdings in shares of Harmony Biosciences by 19.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 61,397 shares of the company’s stock worth $1,852,000 after buying an additional 10,167 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Harmony Biosciences by 13.3% during the second quarter. Dimensional Fund Advisors LP now owns 956,785 shares of the company’s stock worth $28,871,000 after acquiring an additional 112,197 shares during the last quarter. Hsbc Holdings PLC raised its position in Harmony Biosciences by 208.1% during the second quarter. Hsbc Holdings PLC now owns 23,800 shares of the company’s stock valued at $731,000 after purchasing an additional 16,076 shares during the period. Profund Advisors LLC lifted its stake in shares of Harmony Biosciences by 11.1% in the 2nd quarter. Profund Advisors LLC now owns 7,557 shares of the company’s stock valued at $228,000 after purchasing an additional 758 shares during the last quarter. Finally, Public Sector Pension Investment Board boosted its holdings in shares of Harmony Biosciences by 2.9% in the 2nd quarter. Public Sector Pension Investment Board now owns 70,020 shares of the company’s stock worth $2,113,000 after purchasing an additional 1,955 shares during the period. 86.23% of the stock is owned by institutional investors.

Insider Buying and Selling at Harmony Biosciences

In other news, insider Jeffrey Dierks sold 1,123 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $40.00, for a total transaction of $44,920.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 33,126 shares of company stock valued at $1,303,727 in the last three months. 30.80% of the stock is currently owned by corporate insiders.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.